Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

Purpose SWOG S1609 Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) studied the efficacy of ipilimumab combined with nivolumab across multiple rare tumor types. We report the results of the pancreatic neuroendocrine neoplasm (PNEN) cohort.Experimental design Treatment consisted of ipili...

Full description

Saved in:

Bibliographic Details
Main Authors:	Ignacio I Wistuba, Jianhua Zhang, Anup Kasi, Hong Chen, Seunghee Kim-Schulze, Holden T Maecker, Elad Sharon, Razelle Kurzrock, Sacha Gnjatic, Young Kwang Chae, Jiexin Zhang, Jianjun Zhang, Sandip Pravin Patel, Cara L Haymaker, Megan Othus, Charles Blanke, Edwin Parra, Gheath Al-Atrash, Caroline Duault, J Jack Lee, Helen X Chen, Edgar Gonzalez-Kozlova, Dzifa Yawa Duose, Luisa Solis Soto, Ganiraju Manyam, Christopher W Ryan, Jillian Fisher, Bhavana Konda, Mark Walshauser, Caddie Laberiano Fernandez, Raja Luthra, Christine M Magner
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2025-06-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/13/6/e011760.full
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!

Phase II basket trial of Dual Anti-CTLA-4 and anti-PD-1 blockade in Rare Tumors (DART) SWOG S1609: pancreatic neuroendocrine neoplasm (PNEN) cohort

Similar Items